Phase IIa diabetes study termination

We have succesfully finished clinical part of phase II study with patients suffered from diabetes type II.
The aim of the study was to assess safety and efficacy of oral administration of IMP (different doses for each arm including placebo) accompanied to standard treatment, once daily for 14 consecutive days. 80 patients in total were enrolled. No drug related serious adverse events were recorded.

Go back


6th anniversary

This week we celebrate our 6th anniversary. Together with our CEO, clinical team and company's friends, we had a pleasure of being at Aga Zaryan's concert and fancy diner.

Read more …


We are constantly improving our knowledge to assure the best possible quality of our services.

Read more …

Medical Guide Where to Treat 2022

On 29th of April, a special thematic supplement was published in the Polska The Times and newspaper - Medical Guide Where to Treat 2022...

Read more …

BRG Support for Ukraine

We are deeply moved and concerned by the events in Ukraine. As a clinical site, focused on the development of medicine and helping other people,...

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.


scroll to top ▲